Risk factors for neutropenic fever in non-Hodgkin's lymphoma patients with primary granulocyte colony-stimulating factor prophylaxis
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Yu Ri | - |
dc.contributor.author | Kim, Soo-Jeong | - |
dc.contributor.author | Park, Yong | - |
dc.contributor.author | Oh, Sung Yong | - |
dc.contributor.author | Yun, Hwan-Jung | - |
dc.contributor.author | Mun, Yeung-Chul | - |
dc.contributor.author | Kim, Jin Seok | - |
dc.date.accessioned | 2022-02-24T04:40:44Z | - |
dc.date.available | 2022-02-24T04:40:44Z | - |
dc.date.created | 2022-02-07 | - |
dc.date.issued | 2021-09 | - |
dc.identifier.issn | 1226-3303 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/136700 | - |
dc.description.abstract | Background/Aims: Febrile neutropenia (FN) interferes with the proper chemo-therapy dose density or intensity in non-Hodgkin's lymphoma (NHL) patients. Chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) +/- rituximab has an intermediate FN risk. Prophylactic granulocyte col-ony-stimulating factor (G-CSF) support is recommended for patients with other host-related risk factors. Methods: We evaluated the risk factors for FN-related admission in NHL patients who have received primary G-CSF (lenograstim) prophylaxis. Results: Data from 148 patients were analyzed. The incidence of neutropenic fe -ver was 96 events (12.2%), and the median period was 3.85 days (range, 0 to 5.9); the median duration of neutropenia was 4.21 days (range, 3.3 to 5.07). Eighty-three FN-related admissions were reported. Advanced age (> 60 years), female sex, a low albumin level, and prednisone use were associated with FN-related admission in multivariable analysis (p = 0.010, p < 0.001, and p = 0.010, respectively). A compar-ison between diffuse large B-cell lymphoma patients treated with R-CHOP and pegylated G-CSF and those treated with R-CHOP and lenograstim did not reveal significant differences in the FN-related admission rate between the two groups, although the lenograstim-treated group had a higher incidence of severe neutro-penia. Conclusions: Elderly patients, female patients, and patients with low albumin levels need to be actively followed-up for FN even when primary prophylaxis with G-CSF has been used. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | KOREAN ASSOC INTERNAL MEDICINE | - |
dc.subject | FEBRILE NEUTROPENIA | - |
dc.subject | DOSE-INTENSITY | - |
dc.subject | RECEIVING CHEMOTHERAPY | - |
dc.subject | ELDERLY-PATIENTS | - |
dc.subject | CANCER-PATIENTS | - |
dc.subject | FILGRASTIM | - |
dc.subject | MORTALITY | - |
dc.subject | CHOP | - |
dc.subject | PREDICTORS | - |
dc.subject | CNOP | - |
dc.title | Risk factors for neutropenic fever in non-Hodgkin's lymphoma patients with primary granulocyte colony-stimulating factor prophylaxis | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Park, Yong | - |
dc.identifier.doi | 10.3904/kjim.2020.206 | - |
dc.identifier.scopusid | 2-s2.0-85115946781 | - |
dc.identifier.wosid | 000701299600017 | - |
dc.identifier.bibliographicCitation | KOREAN JOURNAL OF INTERNAL MEDICINE, v.36, no.5, pp.1181 - 1189 | - |
dc.relation.isPartOf | KOREAN JOURNAL OF INTERNAL MEDICINE | - |
dc.citation.title | KOREAN JOURNAL OF INTERNAL MEDICINE | - |
dc.citation.volume | 36 | - |
dc.citation.number | 5 | - |
dc.citation.startPage | 1181 | - |
dc.citation.endPage | 1189 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.identifier.kciid | ART002749476 | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | kci | - |
dc.relation.journalResearchArea | General & Internal Medicine | - |
dc.relation.journalWebOfScienceCategory | Medicine, General & Internal | - |
dc.subject.keywordPlus | CANCER-PATIENTS | - |
dc.subject.keywordPlus | CHOP | - |
dc.subject.keywordPlus | CNOP | - |
dc.subject.keywordPlus | DOSE-INTENSITY | - |
dc.subject.keywordPlus | ELDERLY-PATIENTS | - |
dc.subject.keywordPlus | FEBRILE NEUTROPENIA | - |
dc.subject.keywordPlus | FILGRASTIM | - |
dc.subject.keywordPlus | MORTALITY | - |
dc.subject.keywordPlus | PREDICTORS | - |
dc.subject.keywordPlus | RECEIVING CHEMOTHERAPY | - |
dc.subject.keywordAuthor | Albumin | - |
dc.subject.keywordAuthor | Elderly | - |
dc.subject.keywordAuthor | Febrile neutropenia | - |
dc.subject.keywordAuthor | Female | - |
dc.subject.keywordAuthor | Lymphoma | - |
dc.subject.keywordAuthor | non-Hodgkin | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.